Emibetuzumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | HGFR |
Clinical data | |
Other names | LY2875358 |
ATC code |
|
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6356H9810N1694O2014S48 |
Molar mass | 143719.12 g·mol−1 |
Emibetuzumab (INN[1]) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer.[2] It is in phase II trials for patients with NSCLC[3]
This drug was developed by Eli Lilly & Company.
References
- ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Emibetuzumab, American Medical Association.
- ^ Camidge DR, Moran T, Demedts I, Grosch H, Di Mercurio JP, Mileham KF, et al. "A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC".
Categories:
- Articles with short description
- Short description is different from Wikidata
- Drugs not assigned an ATC code
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All stub articles
- Monoclonal antibody stubs
- Monoclonal antibodies